Characteristics | Â |
---|---|
N | 303 |
Age, years—median [IQR] | 58 [19] |
Women—no. (%) | 155 (51.2) |
Body weight, kg—median [IQR] | 77 [19] |
Body mass index, kg/m2—median [IQR] | 27.7 [7.5] |
Systolic blood pressure, mmHg—median [IQR] | 140 [29] |
Diastolic blood pressure, mmHg—median [IQR] | 78 [11] |
Diabetes mellitus—no. (%) |  |
  Type 2 Diabetes—no. (%) | 218 (71.9) |
  Type 1 Diabetes—no. (%) | 85 (28.1) |
Duration of diabetes—median [IQR] | 11 [16] |
Smoke—no. (%) | 95 (31.4) |
Hypertension—no. (%) | 168 (55.4) |
Fasting glucose, mg/dl—median [IQR] | 166 [92] |
HbA1c, %—median [IQR] | 8.8 [2.7] |
Total cholesterol, mg/dl—median [IQR] | 211 [68] |
HDL cholesterol, mg/dl—median [IQR] | 45 [16] |
LDL cholesterol, mg/dl—median [IQR] | 132 [56] |
Triglycerides, mg/dl—median [IQR] | 142 [102] |
Creatinine, mg/dl—median [IQR] | 0.87 [0.26] |
mGFR, ml/min/1.73 m2—median [IQR] | 99.5 [37.3] |
eGFR, ml/min/1.73 m2—median [IQR] | 84.4 [26.3] |
Albuminuria, μg/min—median [IQR] | 7.6 [14.6] |
Glucose-lowering therapy—no. (%) | 255 (84.2) |
  Oral agents—no. (%) | 117 (38.6) |
    Biguanides—no. (%) | 128 (42.2) |
    Sulphonylureas—no. (%) | 85 (28.1) |
    Acarbose—no. (%) | 9 (3.0) |
  Insulin—no. (%) | 152 (50.2) |
  Insulin, UI/die—median [IQR] | 40 [18] |
Lipid-lowering therapy—no. (%) | 26 (8.6) |
Anti-hypertensive therapy—no. (%) | 168 (55.5) |
  ACEi/ARB—no. (%) | 121 (39.9) |
  Beta-Blockers—no. (%) | 18 (5.9) |
  Ca-Blockers—no. (%) | 68 (22.4) |
  Alpha-Blockers—no. (%) | 33 (10.9) |